Executive Director, Global Scientific Communications

About the role

As a new member of the Revolution Medicines team, the Executive Director, Global Scientific Communications will lead the development and execution of a comprehensive scientific communications strategy and team, ensuring alignment across internal and external stakeholders in preparation for the company's first commercial launch in pancreatic cancer and the progression of additional pipeline assets in NSCLC, colorectal cancer, and other solid tumors. Reporting into the SVP, Global Medical Affairs, this role will will be responsible for leading our scientific communications platforms and publication strategies and contribute to medical content supporting the organization's medical and scientific engagement efforts. Key responsibilities include: Publications Strategy & Execution Lead the development and execution of the global publication plans, ensuring alignment with clinical and scientific objectives. Oversee and provide strategic direction for medical writing, publication planning meetings, the submission process, and timely/high-quality scientific communications and publications. Ensure compliance with Good Publication Practices (GPP), ICMJE guidelines, and industry standards. Manage and optimize the use of Datavision or other publication management systems to ensure visibility, collaboration, and compliance across teams. Scientific Communications Platform Develop and maintain the scientific narrative and core communication messages for pipeline programs. Oversee creation of scientific platform materials to ensure consistency and scientific integrity in external communications. Ensure alignment with Medical, Clinical, and Commercial teams for accurate and impactful messaging. Congress Strategy & Scientific Exchange Drive scientific congress planning and execution, including coordination of symposia, abstracts/posters, presentations, and medical booth presence. Identify opportunities to amplify Revolution Medicines' scientific presence at major oncology congresses (e.g., ASCO, ESMO, AACR). Internal Education & Change Management Implement change management strategies to enhance internal understanding of best practices in publications strategy and execution. Educate internal stakeholders on scientific publication standards, compliance requirements, and best-in-class medical communication practices. Build trust across the organization in the Medical Communications function, reinforcing its role as the central authority on publication strategy, planning, and execution. Cross-functional Collaboration & Leadership Serve as a key member of the Medical Excellence team, contributing to medical strategy and launch planning. Partner with Field Medical (MSLs), Medical Information, and Medical Education to ensure a cohesive medical communications and engagement strategy. Work with internal and external stakeholders to contribute to educational content for KOLs, HCPs, and internal teams. Required Skills, Experience and Education: Advanced scientific or medical degree (PhD, PharmD, MD) required 15+ years of experience in Medical Affairs, Medical Communications and publications planning/execution within the biotechnology or pharmaceutical industry. Experience leading scientific publication strategy, medical education initiatives, and external stakeholder engagement. Experience leading a Medical Affairs-focused team Deep understanding of industry guidelines, and best practices (ACCME, PhRMA Code, FDA, OIG, AdvaMed, Sunshine Act). Proven ability to develop and execute medical communication strategies aligned with company and scientific priorities. Expertise in scientific communications planning, data dissemination, and medical writing/publication processes, including authorship guidelines (ICMJE, GPP). Familiarity with clinical development and real-world evidence (RWE) and how these influence scientific communication strategies. Ability to navigate cross-functional partnerships with Clinical, Research/Translational Science, Biostatistics and executive teams. Ability to manage external agency relationships, medical writers, and vendors to ensure quality and compliance in content development. Ability to translate complex scientif

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience